Amneal Pharmaceuticals received abbreviated new drug application approval from the FDA for leuprolide acetate for injection.
Leuprolide acetate injection is indicated in the palliative treatment of advanced prostate cancer. It is the sixth injectable launched this year by Amneal Pharmaceuticals, which is headquartered in Bridgewater, N.J.
“We are making tremendous progress expanding our injectables business,” stated Harsher Singh, the senior vice president for Amneal